Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

As of Jan. 20, the CDC reports that RSV activity has peaked in most of the U.S., particularly among young children—a group ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.